73 Result(s)
within
Paolo Antonio Ascierto
-
Article
Open AccessImpact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma
Treatment duration with checkpoint inhibitors must be optimized to prevent unjustified toxicity, but evidence for the management of cutaneous squamous cell carcinoma is lacking. A retrospective study was perfo...
-
Article
Open AccessThe MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors
Therapy of melanoma has improved dramatically over the last years thanks to the development of targeted therapies (MAPKi) and immunotherapies. However, drug resistance continues to limit the efficacy of these ...
-
Article
Open AccessVein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection
An observational study involving patients recovered from COVID-19 was conducted in order to evaluate the presence/absence of vein wall thickness increasing, according to the severity of pulmonary involvement q...
-
Article
Open AccessComprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres
The current therapeutic algorithm for Advanced Stage Melanoma comprises of alternating lines of Targeted and Immuno-therapy, mostly via Immune-Checkpoint blockade. While Comprehensive Genomic Profiling of soli...
-
Article
Open AccessUpregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin
BRAF-mutant melanoma patients benefit from the combinatorial treatments with BRAF and MEK inhibitors. However, acquired drug resistance strongly limits the efficacy of these targeted therapies in time. Recentl...
-
Article
Open AccessMelanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular traps
Polymorphonuclear neutrophils (PMNs) are the main effector cells in the inflammatory response. The significance of PMN infiltration in the tumor microenvironment remains unclear. Metastatic melanoma is the mos...
-
Article
Open AccessCD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma.
-
Article
Open AccessSequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
The treatment strategy for BRAF-mutated melanoma remains unsatisfactory, although the advent of immune checkpoint inhibition has improved the prognosis of advanced melanoma. This article reports current evidence ...
-
Article
Open AccessIL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
Prognostic factors for initial response of advanced cutaneous squamous cell carcinoma to cemiplimab treatment are lacking. Il-6 has been found to affect immune cell populations which impact tumor development. ...
-
Article
Open AccessConcomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization
The clinical observation showed a potential additive effect of anti-PD-1 agents and cetirizine in patients with advanced melanoma.
-
Article
Management of cutaneous melanoma: radiologists challenging and risk assessment
Melanoma patient remains a challenging for the radiologist, due to the difficulty related to the management of a patient more often in an advanced stage of the disease. It is necessary to determine a stratific...
-
Article
Open AccessBasal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma
To evaluate the capability of basal and one-month differed white blood cells (WBC), neutrophil, lymphocyte and platelet values and their ratios (neutrophils-to-lymphocytes ratio, NLR, and platelets-to-lymphocy...
-
Article
Open AccessVitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients
Immunotherapy with checkpoint inhibitors (CPIs) strongly improved the outcome of metastatic melanoma patients. However, not all the patients respond to treatment and identification of prognostic biomarkers abl...
-
Article
Open AccessCorrection to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
-
Article
Open AccessImmunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis
Coronavirus disease 2019 (COVID-19) global pandemic has created unique challenges to healthcare systems throughout the world. Ensuring subjects’ safety is mandatory especially in oncology, in consideration of ...
-
Article
Open AccessCould asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave
-
Article
Open AccessAvelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
The incidence of Merkel cell carcinoma (MCC), a rare form of skin cancer with a poor prognosis, has increased in Italy in recent decades. Avelumab, an anti-programmed death ligand 1 monoclonal antibody, is app...
-
Article
Open AccessSevere prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature
Tocilizumab is one of the newest therapeutic options for the acute respiratory distress syndrome (ARDS) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) β-coronavi...
-
Article
Open AccessThe clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic
COVID-19 pandemic following the outbreak in China and Western Europe, where it finally lost the momentum, is now devastating North and South America. It has not been identified the reason and the molecular mec...
-
Article
Open AccessTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.
